Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.

Front Immunol · 2021 · PMC8792855 · PMID 35095869

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

Higher rates of physician visits, ranging from 27-33%, were observed in both age groups (<55 and ≥55 years old at the time of exposure) while exposed to alemtuzumab, although this failed to reach significance in the older age group.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.